Breathe Well Live Well
|
Biota Reports Positive Phase IIb Data For Asthmatic Patients With HRV Infection
NASDAQ The Phase II multicenter, randomized, double-blind, placebo controlled study in asthmatic adults with symptomatic, naturally acquired human rhinovirus infection was conducted over two consecutive seasons in 48 centers in the US Subjects received either … Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human … |
View full post on asthma – Google News
|
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human …
MarketWatch (press release) "While the clinical link between HRV infection and loss of asthma control is now widely accepted, Biota is the first company to evaluate the use of an antiviral to treat the infection in asthmatics. This has the potential to be of considerable benefit … |
View full post on asthma – Google News
|
Biota Holdings targeting asthma market with flu drug
Australian Life Scientist Biota Holdingstoday commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who have contracted cold and flu. … HRV Phase II Trial Underway in Patients |
View full post on asthma – Google News